Author | Thomas Powles MBBS, MRCP, MD | OncLive

Author | Thomas Powles MBBS, MRCP, MD

Articles

Dr. Powles on FDA Approval of Pembrolizumab Plus Axitinib in Advanced RCC

April 22, 2019

Video

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the FDA approval of the combination of pembrolizumab (Keytruda) plus axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Dr. Powles on the Results of the KEYNOTE-426 Trial in mRCC

March 15, 2019

Video

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the results of the KEYNOTE-426 trial in metastatic renal cell carcinoma (mRCC).

Dr. Powles on Rationale for KEYNOTE-426 in mRCC

March 11, 2019

Video

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the rationale for the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Dr. Powles on Potential With Durvalumab in Papillary RCC

February 17, 2019

Video

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses durvalumab in combination with a MET inhibitor in the treatment of patients with papillary renal cancer.

x